https://doi.org/10.4081/reumatismo.2021.1437
Successful treatment of COVID-19 induced neutrophilic myositis with intravenous immunoglobulin and corticosteroids: a case report
Submitted: 30 May 2021
Accepted: 27 December 2021
Published: 7 February 2022
Accepted: 27 December 2021
Abstract Views: 4889
PDF: 532
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Neutrophilic myositis (NM) is an inflammatory disorder predominantly characterized by neutrophilic infiltration in the muscles, which is suggested to be an extracutaneous manifestation of neutrophilic dermatosis (ND). NM is a rare disorder which has been occasionally reported in association with hematologic and inflammatory disorders. This case report describes a 45-year-old woman who presented with gradual muscle weakness developed after coronavirus disease 2019 (COVID-19) infection. Electromyography and nerve conduction velocity findings were compatible with inflammatory myopathy and muscle biopsy revealed neutrophilic infiltration. She was successfully treated with intravenous immunoglobulin, prednisolone 1 mg/kg/day and azathioprine 150 mg/day. In conclusion, the COVID-19 infection itself and the drugs used to treat it can cause a number of muscle disorders. Awareness of muscular involvement in COVID-19 infected patients is important for early diagnosis and appropriate treatment.
Marie I, Levesque H, Joly P, et al. Neutrophilic myositis as an extracutaneous manifestation of neutrophilic dermatosis. J Am Acad Dermatol. 2001; 44: 137-9.
DOI: https://doi.org/10.1067/mjd.2001.110903
Kim MK, Park JW, Park SH, et al. Neutrophilic myositis without cutaneous involvement as the first manifestation of acute myeloid leukemia. Korean J Intern Med. 200; 20: 346-8.
DOI: https://doi.org/10.3904/kjim.2005.20.4.346
Christ E, Linka A, Jacky E, et al. Sweet’s syndrome involoving the musculoskeletal system during treatment of promyelocytic leukemia with all-trans retinoic acid. Leukemia. 1996; 10: 731-4.
Melinkeri SR, Gupta RK, Dabadghao S. A Sweet-like syndrome manifesting as gingival hyperplasia and myositis without cutaneous involvement. Ann Hematol. 2002; 81: 397-8.
DOI: https://doi.org/10.1007/s00277-002-0470-7
Qureshi JA, Staugaitis SM, Calabrese LH. Neutrophilic myositis: an extra-intestinal manifestation of ulcerative colitis. J Clin Rheumatol. 2002; 8: 85-8.
DOI: https://doi.org/10.1097/00124743-200204000-00004
Alawneh K, Ashley C, Carlson JA. Neutrophilic myositis as a manifestation of celiac disease: a case report. Clin Rheumatol. 2008; 27: 11-3.
DOI: https://doi.org/10.1007/s10067-007-0801-0
Mosnier E, Rousset P, Hugol D, et al. Neutrophilic myositis sine dermatitis in a neutropenic patient with myelodysplastic syndrome. Ann Hematol. 2013; 92: 551-2.
DOI: https://doi.org/10.1007/s00277-012-1599-7
Matsui Y, Makino T, Torai R, Shimizu T. Neutrophilic myositis developing in a case of systemic lupus erythematosus. Eur J Dermatol. 2020; 30: 432-433.
DOI: https://doi.org/10.1684/ejd.2020.3807
Parra-Medina R, Sarmiento-Monroy JC, Rojas-Villarraga A, et al. Colchicine as a possible therapeutic option in COVID-19 infection. Clin Rheumatol. 2020; 39: 2485-6.
DOI: https://doi.org/10.1007/s10067-020-05247-5
Balagholi S, Dabbaghi R, Eshghi P, et al. Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy. Transfus Apher Sci. 2020; 59: 102993.
DOI: https://doi.org/10.1016/j.transci.2020.102993
Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med. 1987; 316: 1562-8
DOI: https://doi.org/10.1056/NEJM198706183162502
Riggs JE, Schochet SS Jr, Gutmann L, et al. Chronic human colchicine neuropathy and myopathy. Arch Neurol. 1986; 43: 521-3.
DOI: https://doi.org/10.1001/archneur.1986.00520050091033
Uslu S. Myositis due to COVID-19. Postgrad Med J. 2021; 97: 399.
DOI: https://doi.org/10.1136/postgradmedj-2021-139725
Zhang H, Charmchi Z, Seidman RJ, et al. COVID-19-associated myositis with severe proximal and bulbar weakness. Muscle Nerve. 2020; 62: 57-60.
DOI: https://doi.org/10.1002/mus.27003
Beydon M, Chevalier K, Al Tabaa O, et al. Myositis as a manifestation of SARS-CoV-2. Ann Rheum Dis. 2020; 23: 2020-217573.
DOI: https://doi.org/10.1136/annrheumdis-2020-217573
Leung TW, Wong KS, Hui AC, et al. Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series. Arch Neurol. 2005; 62: 1113-7.
DOI: https://doi.org/10.1001/archneur.62.7.1113
Manzano GS, Woods JK, Amato AA. Covid-19-associated myopathy caused by type I interferonopathy. N Engl J Med. 2020; 383: 2389-2390.
DOI: https://doi.org/10.1056/NEJMc2031085
Dalakas MC. Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. Acta Myol. 2020; 39: 289-301.
Cohen PR. Sweet’s syndrome - a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007; 2: 34.
DOI: https://doi.org/10.1186/1750-1172-2-34
How to Cite
Assar, S., Pournazari, M., Soufivand, P., & Mohamadzadeh, D. (2022). Successful treatment of COVID-19 induced neutrophilic myositis with intravenous immunoglobulin and corticosteroids: a case report. Reumatismo, 73(4). https://doi.org/10.4081/reumatismo.2021.1437
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.